Skip to main content
. Author manuscript; available in PMC: 2016 Jun 1.
Published in final edited form as: Br J Psychiatry. 2015 Mar 5;206(6):484–491. doi: 10.1192/bjp.bp.114.151837

Fig. 1. Patients with 22q11.2 deletion syndrome (22q11.2DS) schizophrenia are maintained on a significantly lower therapeutic dose of clozapine than patients with idiopathic schizophrenia (P = 0.002).

Fig. 1

The two 22q11.2DS-schizophrenia patients with doses ≤150 mg had been maintained in this range for at least 1 year; one was receiving adjunct antipsychotic flupentixol (4.5 mg) treatment. Of the three patients in the idiopathic group on a clozapine dose ≤150 mg, one was maintained on this dose for 4 years; the other two discontinued within 9 and 28 weeks, respectively (the latter on adjunct antipsychotic perphenazine (48 mg) treatment) and were not titrated above this low dose range.